Cleo Diagnostics (ASX:COV) Dividend Payout Ratio : 0.00 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Dividend Payout Ratio?

Cleo Diagnostics's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Cleo Diagnostics's Dividend Payout Ratio or its related term are showing as below:

ASX:COV's Dividend Payout Ratio is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 0.43
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-24), the Dividend Yield % of Cleo Diagnostics is 0.00%.

Cleo Diagnostics's Dividends per Share for the months ended in Dec. 2023 was A$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Cleo Diagnostics Dividend Payout Ratio Historical Data

The historical data trend for Cleo Diagnostics's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Dividend Payout Ratio Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Dividend Payout Ratio

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Dividend Payout Ratio	-	-	-

Competitive Comparison of Cleo Diagnostics's Dividend Payout Ratio

For the Medical Devices subindustry, Cleo Diagnostics's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics's Dividend Payout Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Dividend Payout Ratio falls into.

Cleo Diagnostics Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Cleo Diagnostics's Dividend Payout Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Jun. 2023 )	/	EPS without NRI (A: Jun. 2023 )
	=	0	/	-0.066
	=	N/A

Cleo Diagnostics's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.02
	=	N/A

Cleo Diagnostics (ASX:COV) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Cleo Diagnostics Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines